PTX 4.88% 3.9¢ prescient therapeutics limited

Would the incorporation of CellPryme-M into the manufacturing of...

  1. 1,535 Posts.
    lightbulb Created with Sketch. 510
    Would the incorporation of CellPryme-M into the manufacturing of an already approved (or clinically advanced) cell therapy product send that product back to phase 1 clinical trials?

    If so, CellPryme-M may only be attractive to pre-clinical or phase 1 assets.

    Anyone able to answer this question? If not, I'll email the company.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
-0.002(4.88%)
Mkt cap ! $31.40M
Open High Low Value Volume
4.1¢ 4.2¢ 3.9¢ $35.46K 866.3K

Buyers (Bids)

No. Vol. Price($)
2 230290 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 79063 1
View Market Depth
Last trade - 15.45pm 01/10/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.